共 224 条
[1]
Stupp R(2005)Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987-996
[2]
Mason WP(2016)Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio Neuro-Oncology 18 1313-1318
[3]
van den Bent MJ(2015)Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial JAMA 314 2535-2543
[4]
Weller M(2014)A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 699-708
[5]
Fisher B(2013)Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J Clin Oncol 31 4085-4091
[6]
Taphoorn MJ(2013)Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit Clin Neurol Neurosurg 115 1814-1819
[7]
Belanger K(2012)Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 916-926
[8]
Brandes AA(2014)Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 15 1100-1108
[9]
Marosi C(2010)Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide Clin Neurol Neurosurg 112 741-742
[10]
Bogdahn U(2009)Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors Neuro-Oncology 11 825-832